JP2025016451A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025016451A5 JP2025016451A5 JP2024168632A JP2024168632A JP2025016451A5 JP 2025016451 A5 JP2025016451 A5 JP 2025016451A5 JP 2024168632 A JP2024168632 A JP 2024168632A JP 2024168632 A JP2024168632 A JP 2024168632A JP 2025016451 A5 JP2025016451 A5 JP 2025016451A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- sequence
- rna molecule
- seq
- synthetic rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302122P | 2016-03-01 | 2016-03-01 | |
| US62/302,122 | 2016-03-01 | ||
| US201662398451P | 2016-09-22 | 2016-09-22 | |
| US62/398,451 | 2016-09-22 | ||
| JP2018545818A JP7272795B2 (ja) | 2016-03-01 | 2017-03-01 | 優性網膜色素変性の治療のためのａａｖベクター |
| PCT/US2017/020289 WO2017151823A1 (en) | 2016-03-01 | 2017-03-01 | Aav vectors for treatment of dominant retinitis pigmentosa |
| JP2022156496A JP7642211B2 (ja) | 2016-03-01 | 2022-09-29 | 優性網膜色素変性の治療のためのａａｖベクター |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022156496A Division JP7642211B2 (ja) | 2016-03-01 | 2022-09-29 | 優性網膜色素変性の治療のためのａａｖベクター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025016451A JP2025016451A (ja) | 2025-02-04 |
| JP2025016451A5 true JP2025016451A5 (enExample) | 2025-05-30 |
Family
ID=59743213
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545818A Active JP7272795B2 (ja) | 2016-03-01 | 2017-03-01 | 優性網膜色素変性の治療のためのａａｖベクター |
| JP2022156496A Active JP7642211B2 (ja) | 2016-03-01 | 2022-09-29 | 優性網膜色素変性の治療のためのａａｖベクター |
| JP2024168632A Pending JP2025016451A (ja) | 2016-03-01 | 2024-09-27 | 優性網膜色素変性の治療のためのａａｖベクター |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545818A Active JP7272795B2 (ja) | 2016-03-01 | 2017-03-01 | 優性網膜色素変性の治療のためのａａｖベクター |
| JP2022156496A Active JP7642211B2 (ja) | 2016-03-01 | 2022-09-29 | 優性網膜色素変性の治療のためのａａｖベクター |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11118185B2 (enExample) |
| EP (2) | EP3423582B1 (enExample) |
| JP (3) | JP7272795B2 (enExample) |
| CN (2) | CN109154002B (enExample) |
| AU (2) | AU2017227776C1 (enExample) |
| CA (1) | CA3014671A1 (enExample) |
| ES (1) | ES2923877T3 (enExample) |
| IL (2) | IL261014B2 (enExample) |
| WO (1) | WO2017151823A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL261014B2 (en) | 2016-03-01 | 2023-10-01 | Univ Florida | Aav vectors for treatment of dominant retinitis pigmentosa |
| EP3707257A4 (en) * | 2017-11-07 | 2021-12-08 | The University of North Carolina at Chapel Hill | PROCEDURES AND COMPOSITIONS FOR CIRCULAR RNA MOLECULES |
| EP3793566A4 (en) * | 2018-05-15 | 2022-03-16 | University of Washington | Compositions and methods for reducing spliceopathy and treating rna dominance disorders |
| JP7563694B2 (ja) * | 2018-06-01 | 2024-10-08 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | 優性網膜色素変性症の処置のための組成物および方法 |
| GB201817469D0 (en) * | 2018-10-26 | 2018-12-12 | Univ Oxford Innovation Ltd | Gene therapy for retinal disease |
| CN111518813B (zh) * | 2019-02-03 | 2023-04-28 | 武汉纽福斯生物科技有限公司 | 视紫红质的编码序列、其表达载体构建及其应用 |
| WO2021030745A1 (en) * | 2019-08-15 | 2021-02-18 | The Children's Hospital Of Philadelphia | Combined transgene and intron-derived mirna therapy for treatment of sca1 |
| CN113038971B (zh) * | 2020-04-21 | 2022-06-24 | 北京中因科技有限公司 | RHO-adRP基于基因编辑的方法和组合物 |
| CN111926044B (zh) * | 2020-10-12 | 2021-01-22 | 北京大学第三医院（北京大学第三临床医学院） | 结合突变rho基因的核酸分子和试剂盒 |
| EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| WO2025231487A1 (en) * | 2024-05-03 | 2025-11-06 | The Trustees Of The University Of Pennsylvania | Photoreceptor specific promotors for use in gene therapies for treatment of retinal degeneration |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| GB9606961D0 (en) | 1996-04-02 | 1996-06-05 | Farrar Gwyneth J | Genetic strategy III |
| US8551970B2 (en) | 1996-04-02 | 2013-10-08 | Optigen Patents Limited | Genetic suppression and replacement |
| US20040234999A1 (en) | 1996-04-02 | 2004-11-25 | Farrar Gwenyth Jane | Genetic suppression and replacement |
| WO2003104413A2 (en) | 2002-06-05 | 2003-12-18 | University Of Florida | Production of pseudotyped recombinant aav virions |
| WO2004094606A2 (en) | 2003-04-18 | 2004-11-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2 |
| US20070009899A1 (en) | 2003-10-02 | 2007-01-11 | Mounts William M | Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases |
| WO2005090572A2 (en) | 2004-03-24 | 2005-09-29 | Oncotherapy Science, Inc. | Compositions and methods for treating pancreatic cancer |
| US20080221057A1 (en) | 2007-02-16 | 2008-09-11 | Wyeth | Secreted protein ccdc80 regulates adipocyte differentiation |
| US20120322861A1 (en) | 2007-02-23 | 2012-12-20 | Barry John Byrne | Compositions and Methods for Treating Diseases |
| EP2140004B1 (en) * | 2007-04-12 | 2022-01-12 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Genetic suppression and replacement |
| CA2702701A1 (en) | 2007-08-03 | 2009-03-19 | Melba Ketchum | Compositions, methods and systems for the simultaneous determination of parentage, identity, sex, genotype and/or phenotype, and breed determination in animals |
| US8450473B2 (en) * | 2009-04-30 | 2013-05-28 | The Research Foundation Of State University Of New York | Compositions and methods for therapy of macular degeneration |
| CA2801523C (en) | 2010-07-30 | 2021-08-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| CN102061308B (zh) | 2010-10-29 | 2013-05-08 | 北京未名凯拓作物设计中心有限公司 | 一种用百草枯筛选转基因植物的方法 |
| CN102061305B (zh) | 2010-12-15 | 2012-07-18 | 深圳市百恩维生物科技有限公司 | 一种多ShRNA高效协同沉默基因方法及载体 |
| US20130064815A1 (en) | 2011-09-12 | 2013-03-14 | The Trustees Of Princeton University | Inducing apoptosis in quiescent cells |
| EP2855684A1 (en) | 2012-05-25 | 2015-04-08 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Vector for the selective silencing of a gene in astrocytes |
| US20140289881A1 (en) | 2013-03-14 | 2014-09-25 | Commonwealth Scientific And Industrial Research Organisation | Double-stranded rna |
| ES2760263T3 (es) | 2014-03-21 | 2020-05-13 | Genzyme Corp | Tratamiento génico de la retinitis pigmentaria |
| BR112017017178A2 (pt) | 2015-02-26 | 2018-04-03 | Ionis Pharmaceuticals Inc | moduladores específicos de alelo de rodopsina de p23h |
| EP4008780A1 (en) | 2015-04-30 | 2022-06-08 | The Trustees of Columbia University in the City of New York | Gene therapy for autosomal dominant diseases |
| WO2017137493A1 (en) | 2016-02-09 | 2017-08-17 | Fondazione Telethon | Synthetic promoters and uses thereof |
| US20170348387A1 (en) | 2016-02-29 | 2017-12-07 | The Trustees Of The University Of Pennsylvania | Aav-mediated gene therapy for nphp5 lca-ciliopathy |
| IL261014B2 (en) | 2016-03-01 | 2023-10-01 | Univ Florida | Aav vectors for treatment of dominant retinitis pigmentosa |
-
2017
- 2017-03-01 IL IL261014A patent/IL261014B2/en unknown
- 2017-03-01 EP EP17760752.0A patent/EP3423582B1/en active Active
- 2017-03-01 CA CA3014671A patent/CA3014671A1/en active Pending
- 2017-03-01 EP EP22170988.4A patent/EP4119668A1/en active Pending
- 2017-03-01 CN CN201780014309.8A patent/CN109154002B/zh active Active
- 2017-03-01 AU AU2017227776A patent/AU2017227776C1/en active Active
- 2017-03-01 IL IL302455A patent/IL302455A/en unknown
- 2017-03-01 ES ES17760752T patent/ES2923877T3/es active Active
- 2017-03-01 WO PCT/US2017/020289 patent/WO2017151823A1/en not_active Ceased
- 2017-03-01 CN CN202210934990.0A patent/CN115896106A/zh active Pending
- 2017-03-01 US US16/081,307 patent/US11118185B2/en active Active
- 2017-03-01 JP JP2018545818A patent/JP7272795B2/ja active Active
-
2021
- 2021-05-21 US US17/327,609 patent/US20210324387A1/en active Pending
-
2022
- 2022-09-29 JP JP2022156496A patent/JP7642211B2/ja active Active
-
2023
- 2023-09-27 AU AU2023237106A patent/AU2023237106B2/en active Active
-
2024
- 2024-09-27 JP JP2024168632A patent/JP2025016451A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025016451A5 (enExample) | ||
| JP2022185052A5 (enExample) | ||
| US9150863B2 (en) | Compositions and methods for siRNA inhibition of angiogenesis | |
| EP2633051B1 (en) | Hbv treatment | |
| US7872118B2 (en) | siRNA and methods of manufacture | |
| US8470792B2 (en) | Compositions and methods for selective inhibition of VEGF | |
| JP2019511216A5 (enExample) | ||
| US8227444B2 (en) | Compositions and methods for inhibition of VEGF | |
| JP2024119830A5 (enExample) | ||
| JP2020503014A5 (enExample) | ||
| JP2019513395A5 (enExample) | ||
| CA2542871A1 (en) | Retroviral vectors for delivery of interfering rna | |
| US20070036740A1 (en) | Modulation of hair growth | |
| KR20130012095A (ko) | ＴＧＦ－β１ 발현을 억제하는 ｓｈＲＮＡ | |
| RU2018142797A (ru) | Средства для лечения инфекции вируса гепатита в (hbv) и их применение | |
| JPWO2019232517A5 (enExample) | ||
| JPWO2022011262A5 (enExample) | ||
| JPWO2020047476A5 (enExample) | ||
| CN100494380C (zh) | 一组抗丙型肝炎病毒感染及防治丙型肝炎的核苷酸序列、其片段及其应用 | |
| JPWO2022245734A5 (enExample) | ||
| JPWO2022061108A5 (enExample) | ||
| JPWO2020077412A5 (enExample) | ||
| HK1234090B (en) | Hbv treatment |